DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Clinical features and treatment outcomes of 79 infants with immune thrombocytopenic purpura.

Author(s): Sandoval C, Visintainer P, Ozkaynak MF, Tugal O, Jayabose S

Affiliation(s): Department of Pediatrics and the Graduate School of Health Sciences, New York Medical College, Valhalla, New York 10595, USA. claudio_sandoval@nymc.edu

Publication date & source: 2004-01, Pediatr Blood Cancer., 42(1):109-12.

BACKGROUND: To determine the clinical features and treatment outcomes of infants with immune thrombocytopenic purpura (ITP). METHODS: Retrospective analysis of 79 infant ITP patients treated from 1987 to 2002. The data abstracted comprised age, gender, clinical features, and treatment outcomes. A score test for the trend in the odds ratios was used to determine the risk of chronic ITP with advancing age. The infants were compared to a group of contemporaneous older children with regard to bleeding severity and incidence of chronic ITP. RESULTS: The 34 female and 45 male infants had a median age of 16 months. Seventy-four presented with purpura, four with viral illnesses, and one was asymptomatic. Eight percent had active mucosal bleeding. The median platelet count was 8,000/microl. Forty infants received intravenous immunoglobulin, nine intravenous anti-D immunoglobulin, six steroids, and seven were observed without treatment. Fifty-five (76%) responded to a single course of treatment. Only 9% of infants developed chronic ITP compared to 18% of children between the ages of 25 and 119 months and 47% of children 120 months or older (P<0.0005). CONCLUSIONS: Infants with ITP respond favorably to treatment and are less likely to develop chronic ITP compared to older children. Copyright 2003 Wiley-Liss, Inc.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017